Krilogy Financial LLC Acquires New Stake in Caris Life Sciences, Inc. $CAI

Krilogy Financial LLC bought a new stake in Caris Life Sciences, Inc. (NASDAQ:CAI) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 25,126 shares of the company’s stock, valued at approximately $746,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Renaissance Technologies LLC raised its position in shares of Caris Life Sciences by 36.4% during the 1st quarter. Renaissance Technologies LLC now owns 449,900 shares of the company’s stock valued at $8,044,000 after buying an additional 120,000 shares in the last quarter. Maxi Investments CY Ltd bought a new stake in shares of Caris Life Sciences during the 2nd quarter worth $3,754,000. Sei Investments Co. lifted its holdings in shares of Caris Life Sciences by 2,348.6% during the 1st quarter. Sei Investments Co. now owns 598,712 shares of the company’s stock worth $10,705,000 after acquiring an additional 574,261 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Caris Life Sciences by 50.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 153,512 shares of the company’s stock worth $2,745,000 after acquiring an additional 51,696 shares during the last quarter. Finally, Lazard Asset Management LLC grew its position in Caris Life Sciences by 26.0% in the first quarter. Lazard Asset Management LLC now owns 305,911 shares of the company’s stock worth $5,470,000 after acquiring an additional 63,132 shares in the last quarter.

Caris Life Sciences Stock Down 3.8%

Shares of NASDAQ CAI opened at $30.56 on Friday. Caris Life Sciences, Inc. has a one year low of $14.19 and a one year high of $33.13. The company has a debt-to-equity ratio of 0.66, a current ratio of 5.53 and a quick ratio of 4.88. The firm’s 50 day simple moving average is $27.12 and its two-hundred day simple moving average is $20.92. The stock has a market capitalization of $8.64 billion, a P/E ratio of 84.89 and a beta of 0.86.

Insider Transactions at Caris Life Sciences

In other news, insider Brian Brille sold 400,000 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $30.33, for a total value of $12,132,000.00. Following the completion of the sale, the insider directly owned 230,303 shares in the company, valued at approximately $6,985,089.99. The trade was a 63.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider John Russel Denton sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $31.82, for a total transaction of $238,650.00. Following the completion of the sale, the insider directly owned 174,855 shares of the company’s stock, valued at $5,563,886.10. This trade represents a 4.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 1,004,712 shares of company stock worth $27,205,419. 50.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CAI. TD Cowen increased their target price on Caris Life Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday. BTIG Research raised their price target on Caris Life Sciences from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. lifted their price target on Caris Life Sciences from $25.00 to $35.00 and gave the stock an “overweight” rating in a research note on Wednesday. Weiss Ratings lowered Caris Life Sciences from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, October 2nd. Finally, Evercore reiterated an “outperform” rating and issued a $26.00 price objective on shares of Caris Life Sciences in a report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $27.82.

Caris Life Sciences Profile

Caris Life Sciences is a biotechnology company focused on precision oncology and the use of molecular and artificial intelligence technologies to support cancer diagnosis and treatment decisions. The company analyzes tumor and blood samples to identify genetic, molecular and other biological characteristics that may help physicians select targeted therapies and develop individualized treatment plans.

Its offerings include comprehensive tumor profiling, molecular testing and data-driven clinical support for oncologists and other healthcare providers.